[{"id":"876ce078-02f8-4b29-96fc-e46147d9c92f","acronym":"PYX-201-101","url":"https://clinicaltrials.gov/study/NCT05720117","created_at":"2023-09-21T18:11:07.087Z","updated_at":"2025-02-25T16:39:39.072Z","phase":"Phase 1","brief_title":"Study of PYX-201 in Solid Tumors","source_id_and_acronym":"NCT05720117 - PYX-201-101","lead_sponsor":"Pyxis Oncology, Inc","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e micvotabart pelidotin (PYX-201)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-06"}]